Report cover image

Global & Japan Cancer Therapeutics Market to 2031

Publisher Business Market Insights
Published Jun 04, 2025
Length 100 Pages
SKU # BMKS20063465

Description

Japan, known for having one of the highest life expectancies globally—approximately 85 years at birth, according to the United Nations' 2021 World Population Prospectus—is facing a growing healthcare challenge due to its aging population. At least 500,000 individuals in the country are aged 65 or older. Projections from Japan’s National Institute of Population and Social Security Research estimate that by 2050, 37.7% of the population will fall into this age group. This demographic trend, along with an increasing number of cancer cases, is expected to significantly boost demand for effective cancer treatments.

According to data from GLOBOCAN 2022 (WHO), Japan recorded approximately 1 million new cancer diagnoses and around 420,000 cancer-related deaths in that year. Specifically, breast cancer accounted for 92,024 new cases and caused 17,081 deaths in 2020, representing 8.9% of all cancer diagnoses in the country. These figures underscore the growing need for advanced cancer therapeutics in Japan.

In response, the Japanese Ministry of Health, Labour and Welfare (MHLW) has been actively approving new cancer treatments. In March 2023, the agency authorized the use of fam-trastuzumab deruxtecan-nxki for adult patients with HER2-low, unresectable, or recurrent breast cancer who had previously undergone chemotherapy. More recently, in September 2024, the MHLW approved Fruzaqla (fruquintinib) for treating patients with unresectable metastatic colorectal cancer (mCRC) that has progressed despite prior chemotherapy. This marks the first approval of a novel targeted therapy for mCRC in Japan in over ten years, regardless of biomarker status—highlighting the country’s growing focus on expanding and modernizing cancer treatment options.

Table of Contents

100 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Data Triangulation and Validation:
4. Japan Cancer Therapeutics Market Landscape
4.1 Overview
4.2 Ecosystem Analysis
4.2.1 List of Vendors in the Value Chain
5. Cancer Therapeutics Market Key Market Dynamics
5.1 Cancer Therapeutics Market – Key Market Dynamics
5.2 Market Drivers
5.3 Market Restraints
5.4 Market Opportunities
5.5 Future Trends
5.6 Impact of Drivers and Restraints
6. Japan Cancer Therapeutics Market – Analysis
6.1 Japan Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
6.2 Japan Cancer Therapeutics Market Revenue and Forecast Analysis
7. Japan Cancer Therapeutics Market Analysis – by Therapy Types
7.1 Japan Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
8. Japan Cancer Therapeutics Market Analysis – by Indications
8.1 Japan Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
9. Japan Cancer Therapeutics Market Analysis – by Distribution Channel
9.1 Japan Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
10. Competitive Landscape
10.1 Heat Map Analysis by Key Players
10.1 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.2 Partnerships and Collaborations
11.2 Other Developments
12. Company Profiles
12.1 Bristol-Myers Squibb Co
12.1. 1 Key Facts
12.1. 2 Business Description
12.1. 3 Products and Services
12.1. 4 Financial Overview
12.1. 5 SWOT Analysis
12.1. 6 Key Developments
12.2 AbbVie Inc
12.2. 1 Key Facts
12.2. 2 Business Description
12.2. 3 Products and Services
12.2. 4 Financial Overview
12.2. 5 SWOT Analysis
12.2. 6 Key Developments
12.3 Johnson & Johnson
12.3. 1 Key Facts
12.3. 2 Business Description
12.3. 3 Products and Services
12.3. 4 Financial Overview
12.3. 5 SWOT Analysis
12.3. 6 Key Developments
12.4 F. Hoffmann-La Roche Ltd
12.4. 1 Key Facts
12.4. 2 Business Description
12.4. 3 Products and Services
12.4. 4 Financial Overview
12.4. 5 SWOT Analysis
12.4. 6 Key Developments
12.5 Pfizer Inc
12.5. 1 Key Facts
12.5. 2 Business Description
12.5. 3 Products and Services
12.5. 4 Financial Overview
12.5. 5 SWOT Analysis
12.5. 6 Key Developments
12.6 AstraZeneca Plc
12.6. 1 Key Facts
12.6. 2 Business Description
12.6. 3 Products and Services
12.6. 4 Financial Overview
12.6. 5 SWOT Analysis
12.6. 6 Key Developments
12.7 Merck KGaA
12.7. 1 Key Facts
12.7. 2 Business Description
12.7. 3 Products and Services
12.7. 4 Financial Overview
12.7. 5 SWOT Analysis
12.7. 6 Key Developments
12.8 Novartis AG
12.8. 1 Key Facts
12.8. 2 Business Description
12.8. 3 Products and Services
12.8. 4 Financial Overview
12.8. 5 SWOT Analysis
12.8. 6 Key Developments
12.9 Astellas Pharma Inc
12.9. 1 Key Facts
12.9. 2 Business Description
12.9. 3 Products and Services
12.9. 4 Financial Overview
12.9. 5 SWOT Analysis
12.9. 6 Key Developments
12.10 Eli Lilly and Co
12.10. 1 Key Facts
12.10. 2 Business Description
12.10. 3 Products and Services
12.10. 4 Financial Overview
12.10. 5 SWOT Analysis
12.10. 6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations
TABLE OF TABLES
Table 1. Japan Cancer Therapeutics Market Segmentation
Table 2. List of Vendors
Table 3. Japan Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
Table 4. Japan Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
Table 5. Japan Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
Table 6. Japan Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
Table 7. Japan Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
Table 8. Japan Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
Table 9. Japan Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 10. Japan Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 11. List of Abbreviations
TABLE OF FIGURES
Figure 1. Impact Analysis of Drivers and Restraints
Figure 2. Japan Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
Figure 3. Heat Map Analysis by Key Players
Figure 4. Company Positioning and Concentration

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us